Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 1

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 1
---
 | ​ | ​ | Development Pipeline                   |
| 12                                        | ​ | ​ | $10.8BN                            | ​ | ​ | ~90                                    |
| assets with 2024 net revenues > $1.0BN    | ​ | ​ | increased $3.0BN compared to 2023* | ​ | ​ | active clinical and device programs*** |

The measures set forth in this table were calculated as of 12/31/2024.

| * | Reflects a non-GAAP measure and is adjusted for certain items, which are reconciled in Appendix B. Operational growth is presented at constant currency rates that reflect comparative local currency net revenues at the prior year’s foreign exchange rates. |

| ** | Growth Platform reflects total net revenues less Humira net revenues. |

| *** | Compounds, devices or indications in development individually or under collaboration or license agreements. |

Strong operational execution

| ● | Total net revenues of $56.3 billion, driven by strong performance from our Growth Platform, reflected a return to top-line growth in the first full year following the U.S. Humira loss of exclusivity (LOE). |

| o | Key asset performance drove Growth Platform net revenues of $47.3 billion, an increase of 18.6% compared to 2023. |

| o | AbbVie’s Growth Platform comprised 84% of total net revenues in 2024, with double-digit sales growth for six key assets, including growth of over 50% for Skyrizi and Rinvoq. |

| ● | Reported diluted EPS of $2.39 on a GAAP basis and adjusted diluted EPS of $10.12. See Appendix B for the reconciliation. |

| ● | Generated operating cash flow of $18.8 billion. |

Advancing new medicines and strengthening our innovative R&D pipeline

| ● | Achieved several significant regulatory approvals, including Skyrizi for the treatment of adults with moderately to severely active ulcerative colitis (UC); Vyalev for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD); Epkinly for the treatment of adults with relapsed/refractory (r/r) follicular lymphoma (FL); Elahere for the treatment of folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies; and Botox Cosmetic for temporary improvement in the appearance of moderate to severe